Arx Limited

Bioxcel Therapeutics, Inc.

Adhesives Research, Inc.

Sunovion Pharmaceuticals Inc.

Cynapsus Therapeutics, Inc.

Hercon Laboratories Corporation

Project Pegasus Sub Acquisition Ulc

Sunovion Cns Development Canada Ulc

Scott David Barnhart

Anthony John Giovinazzo

Michael Clinton Koons

Frank Yocca

David Christian Hanley

Chetan Dalpatbhai Lathia

Nathan Bryson

Vasukumar Kakumanu

Andrew P Full

Cathy M Moritz

Matthew K Musho

John H Lind

William G Meathrel

Mary Robertson

Madhu Hariharan

William C Baer

Nathan A Meyer

Susan R Newsom

Abraham Anonuevo

Eric Lakatosh

Jordan Dubow

Thierry Bilbault

George Cramer

Elio P Mariani

Nathan John Bryson

Madhu Sudan Hariharan

Dissolvable unit dose film constructs are made by providing a muco-adhesive composition including a muco-adhesive polymer matrix in which the muco-adhesive polymer matrix has a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof and a liquid carrier. The method further includes drying the muco-adhesive composition to remove at least a portion of the liquid carrier, forming a muco-adhesive film substrate, forming a composition for an active layer, the composition including a polymer matrix in which the polymer matrix for the active layer composition includes a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof, an active ingredient and a liquid carrier. The method further includes depositing the composition for the active layer onto the muco-adhesive substrate as a plurality of individual volumes and removing the liquid carrier from the plurality of deposited individual volumes to form a plurality of dissolvable film active layers on the muco-adhesive substrate.

Dispensing method for producing dissolvable unit dose film constructs

Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Film formulations containing dexmedetomidine and methods of producing them

The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Sublingual films

Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an 'off' episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g&#xd7;mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.

Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa

Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa

A dissolvable film for delivering a pharmaceutical agent comprises a first water soluble polymer in an amount of from 2 to 35 weight percent and having a molecular weight from about 5,000 daltons to about 49,000 daltons; a second water soluble polymer in an amount of from 2 to 35 weight percent and having a molecular weight greater than 60,000 daltons; and a pharmaceutically active ingredient. The film has a thickness of about 20 microns to about 1200 microns and is configured to disintegrate after contact with a mucous membrane and thereby release the active ingredient.

Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents

A method of forming a kit containing multiple dissolvable unit dose constructs includes providing at least one muco-adhesive composition comprising a polymer matrix, the polymer matrix comprising a water soluble polymer, an active ingredient and a liquid carrier; forming a plurality of dissolvable thin film unit dose constructs by depositing the at least one composition onto a substrate wherein at least two adjacent dissolvable thin film unit dose constructs are formed having a pre-determined different identifiable physical characteristic with respect to the other as a result of the depositing; and packaging the plurality of dissolvable thin films in a single package to form a kit.

Production of unit dose constructs

Dissolvable unit dose constructs and their method of manufacture are disclosed in which the unit dose constructs are formed of a composition including a polymer matrix that includes a water soluble polymer, active ingredient, and a liquid carrier. The composition is deposited directly, such as by stenciling, to form individual unit doses without the need to cut and convert long, continuous rolls of film.

Growing community of inventors

York, PA, United States of America

Scott David Barnhart